- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
- Sage Therapeutics to Present at Upcoming March Investor Conferences
- Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
More ▼
Key statistics
As of last trade, SAGE Therapeutics Inc (SAGE:NMQ) traded at 13.10, 19.96% above the 52 week low of 10.92 set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.91 |
---|---|
High | 13.38 |
Low | 12.74 |
Bid | 13.09 |
Offer | 13.11 |
Previous close | 12.89 |
Average volume | 1.55m |
---|---|
Shares outstanding | 60.11m |
Free float | 52.56m |
P/E (TTM) | -- |
Market cap | 774.78m USD |
EPS (TTM) | -9.05 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 20:07 BST.
More ▼